This activity is part
2 in a 3-part webinar curriculum.
Program Description
The primary treatment goal for people living with diabetes and chronic kidney disease (CKD) is the prevention of disease progression. Emerging data from recent clinical trials have established new strategies to treat diabetes and CKD that pharmacists must be aware of to reduce the residual risk of progression to end-stage kidney disease and cardiovascular morbidity and mortality. Pharmacists on the multidisciplinary care team must understand the nuances of current therapies. The discussion will include strategies for the concomitant use of available therapies and the potential place in the treatment paradigm for new and emerging agents, including non-steroidal mineralocorticoid receptor antagonists. This webinar will equip pharmacists with guideline recommendations and safety and efficacy data for new and emerging agents to make informed interventions for people living with diabetes and CKD.
Target audience: Health-system, retail, and specialty pharmacists
Type of activity: Application
Release date: September 7, 2023
Expiration date: November 7, 2023
Time to complete activity: 1.0 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the latest guideline recommendations for diabetes management in chronic kidney disease (CKD)
- Examine the role of new and emerging treatments in clinical practice
- Determine the value of novel drug therapies in the treatment of CKD based on clinical safety and efficacy data
Calvin J. Meaney, PharmD, BCPS
Clinical Associate Professor
Interim Head, Division of Outcomes and Practice Advancement
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
University at Buffalo
Buffalo, New York
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-309-L01-P. The activity is available for CE credit through November 7, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Calvin J. Meaney, PharmD, BCPS, has the following financial relationships with commercial interests to disclose:
Consultant: Wolters Kluwer
Speakers Bureau: GSK
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Rush, PharmD; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms